https://orcid.org/0000-0001-9867-8861
Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Turki AlAmeel, Abdulelah AlMutairdi & Badr Al-Bawardy. (2023) Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials. Clinical and Experimental Gastroenterology 16, pages 147-167.
Read now
Read now
Noah Becher, Arun Swaminath & Keith Sultan. (2022) A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application. Therapeutics and Clinical Risk Management 18, pages 913-927.
Read now
Read now
Jin Wu, Yiting Luo, Yan Shen, Yuyao Hu, Fangyuan Zhu, Jiaqian Wu & Yingchao Liu. (2022) Integrated Metabonomics and Network Pharmacology to Reveal the Action Mechanism Effect of Shaoyao Decoction on Ulcerative Colitis. Drug Design, Development and Therapy 16, pages 3739-3776.
Read now
Read now
Articles from other publishers (17)
Yi-Ping Tao, Heng-Yan Zhu, Qian-Yuan Shi, Cai-Xia Wang, Yu-Xin Hua, Han-Yin Hu, Qi-Yin Zhou, Zi-Lu Zhou, Ying Sun, Xiao-Min Wang, Yu Wang, Ya-Ling Zhang, Yan-Jun Guo, Zi-Ying Wang, Xuan Che, Chun-Wei Xu, Xian-Chao Zhang, Michal Heger, Su-Ping Tao, Xin Zheng, Ying Xu, Lei Ao, Ai-Jun Liu, Sheng-Bing Liu, Shu-Qun Cheng & Wei-Wei Pan. (2023) S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway. Oncogene 42:47, pages 3491-3502.
Crossref
Crossref
Pauline Wils & Laurent Peyrin-Biroulet. (2023) Etrasimod for the treatment of ulcerative colitis. Immunotherapy 15:5, pages 311-321.
Crossref
Crossref
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, Marla C Dubinsky, Julian Panes, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J Rabbat, Michael Chiorean, Douglas C Wolf, Bruce E Sands, Geert D'Haens, Silvio Danese, Martina Goetsch & Brian G Feagan. (2023) Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet 401:10383, pages 1159-1171.
Crossref
Crossref
Niloofar Najarzadegan, Mahboobeh Madani, Masoud Etemadifar & Nahad Sedaghat. (2022) Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model. PLOS ONE 17:12, pages e0278488.
Crossref
Crossref
Giacomo CAIO, Lisa LUNGARO, Giuseppe CHIARIONI, Fiorella GIANCOLA, Fabio CAPUTO, Matteo GUARINO, Umberto VOLTA, Gianni TESTINO, Rinaldo PELLICANO, Giorgio ZOLI & Roberto DE GIORGIO. (2022) Beyond biologics: advanced therapies in inflammatory bowel diseases. Minerva Gastroenterology 68:3.
Crossref
Crossref
Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji & Tao Wu. (2022) Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases. Biomedicine & Pharmacotherapy 153, pages 113341.
Crossref
Crossref
Paulina Núñez F, Rodrigo Quera, Constanza Bay, Fabiola Castro & Gabriel Mezzano. (2022) Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease. Journal of Crohn's and Colitis 16:7, pages 1168-1176.
Crossref
Crossref
Duaa Ahmed Elhag, Manoj Kumar, Marwa Saadaoui, Anthony K. Akobeng, Fatma Al-Mudahka, Mamoun Elawad & Souhaila Al Khodor. (2022) Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. International Journal of Molecular Sciences 23:13, pages 6966.
Crossref
Crossref
Jie Wang, Idan Goren, Bo Yang, Sinan Lin, Jiannan Li, Michael Elias, Claudio Fiocchi & Florian Rieder. (2021) Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 55:3, pages 277-291.
Crossref
Crossref
Gerard Honig, Paul B Larkin, Caren Heller & Andrés Hurtado-Lorenzo. (2021) Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 27:Supplement_2, pages S1-S16.
Crossref
Crossref
Victor V. Zhirnov, Yevheniia S. Velihina, Oleg P. Mitiukhin & Volodymyr S. Brovarets. (2021)
Intrinsic drug potential of oxazolo[5,4‐
d
]pyrimidines and oxazolo[4,5‐
d
]pyrimidines
. Chemical Biology & Drug Design 98:4, pages 561-581.
Crossref
Crossref
Claudia Günther, Veit Rothhammer, Marisa Karow, Markus Neurath & Beate Winner. (2021) The Gut-Brain Axis in Inflammatory Bowel Disease—Current and Future Perspectives. International Journal of Molecular Sciences 22:16, pages 8870.
Crossref
Crossref
Tamara Pérez-Jeldres, Manuel Alvarez-Lobos & Jesús Rivera-Nieves. (2021) Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. Drugs 81:9, pages 985-1002.
Crossref
Crossref
Juan S. Lasa, Pablo A. Olivera, Stefanos Bonovas, Silvio Danese & Laurent Peyrin-Biroulet. (2021) Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. Drug Safety 44:6, pages 645-660.
Crossref
Crossref
Ki-Uk Kim, Jisu Kim, Wan-Hoon Kim, Hyeyoung Min & Chang Hwan Choi. (2021) Treatments of inflammatory bowel disease toward personalized medicine. Archives of Pharmacal Research 44:3, pages 293-309.
Crossref
Crossref
Ferdinando D’Amico, Laurent Peyrin-Biroulet, Silvio Danese & Gionata Fiorino. (2020) New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?. Current Opinion in Pharmacology 55, pages 141-150.
Crossref
Crossref
Khadija El-Hindi, Sebastian Brachtendorf, Jennifer Christina Hartel, Stephanie Oertel, Kerstin Birod, Sandra Trautmann, Dominique Thomas, Thomas Ulshöfer, Andreas Weigert, Olaf Utermöhlen, Martin Krönke & Sabine Grösch. (2020) Ceramide Synthase 5 Deficiency Aggravates Dextran Sodium Sulfate-Induced Colitis and Colon Carcinogenesis and Impairs T-Cell Activation. Cancers 12:7, pages 1753.
Crossref
Crossref